doi:10.16597/j.cnki.issn.1002-154x.2022.12.007
阿贝西利药物的研究进展
王业涤 刘艳佳 陈博 王博*
(佳木斯大学附属第一医院 肿瘤科,黑龙江 佳木斯 154003)
Research Progress of Abemaciclib
Wang Yedi; Liu Yanjia; Chen Bo ;Wang Bo∗;
(Oncology, The First Affiliated Hospital of Jiamusi University, Heilongjiang Jiamusi 154003)
摘要:
阿贝西利是经 FDA 批准上市的新型细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂,临床用于治疗晚期或转移性乳腺癌。作者分别对阿贝西利合成方法、药理学及功效和作用机制进行了总结和概括,以期为相关研究人员提供参考。
关键词：阿贝西利；药物合成；药物作用机制；
Abstract：
Abemaciclib is a novel cell cycle protein-dependent kinase 4/6 (CDK4/6) inhibitor approved by FDA for the clinical treatment of advanced or metastatic breast cancer. The paper summarized and outlined the synthesis method, mechanism of action and efficacy of abemaciclib, respectively, in order to provide a reference for related researchers
Keywords：Abemaciclib; drug synthesis; drug mechanism of action;